-
Recap of CSR stories on Business Wire
-
-
FY22 Investment Brings Program Total to Nearly $40 Million, Adding 21 New Grant Partners
-
Company Continues to Improve Equity Among Under-Resourced Communities Focusing on Areas of Health, Education, Environment and Providing
-
First U.S. CSR Report, Takeda Cares for Communities, Highlights Program Efforts Since its FY21 Launch
-
The three-day event returns to fully in-person for the first time in more than three years, featuring 200+ speakers, including government officials, philanthropists, scientists, and more
-
Takeda (TSE:4502/ NYSE:TAK), a global biopharmaceutical leader, and Discovery Education, the worldwide edtech leader, today announced a new partnership focused on transformative health equity education.
-
Event will Highlight and Explore Collaborative Efforts to Overcome Inequities Faced by Minoritized Communities
-
Recap of CSR stories on Business Wire
-
-
Since its Launch in 2016, New Partnerships Bring Total Global CSR Program Contributions to JPY 19.7 Billion (Approx. USD 140.7 million) Across 24 Programs in 79 Countries
-
More Than 23,000 Takeda Employees Voted on New Partnerships Selecting Ipas, Plan International, Pure Earth and United Nations Population Fund (UNFPA)
-
Global CSR Program Partnerships Help Takeda Advance Disease Prevention, Empower the Health Workforce and Strengthen Health Systems Across the World
-
New Nonprofit Cybersecurity Portfolio commits $1M+ as part of Okta’s 3-year Nonprofit Technology Initiative
-
Today, the Montreal Neurological Institute-Hospital at McGill University (The Neuro) announced a new research collaboration with Illumina, along with Takeda Development Center Americas, Inc., and pharmaceutical powerhouse Roche.
-
− Takeda is enhancing its Corporate Social Responsibility program with significant commitment to underrepresented communities in the U.S.
− U.S. Program prioritizes health equity, climate resiliency, K-8 math literacy and food security across the country
− 20 grantees selected as FY2021 program partners
-
World Quality Week’s theme this year of Sustainability aligns extremely well with Takeda’s focus on Patient, People and Planet.
-
During the 76th United Nations (UN) General Assembly, Takeda’s Global CSR Program hosted a panel discussion to discuss why health systems strengthening (HSS) is more important than ever. Panelists dove into what HSS looks like in practice and why it’s so critical today.
-
- Global employees based across 80 countries and regions voted to support new partnerships with IntraHealth International, Jhpiego, Pathfinder International and the World Food Programme
- New partnerships bring total Global CSR Program contributions to JPY 16.5 billion across 20 programs in 72 countries following launch in 2016
- Global CSR Program partnerships help Takeda advance disease prevention measures, empower the health workforce and support health systems
-
Despite the unprecedented challenges of the past year, we continued to meet the needs of patients and deliver positive results both for shareholders and the communities we serve.
-
Meet the people who are living and breathing the Blueprint in the second episode focusing on the importance of screening of NCDs of a 5-part series of our pilot program in Meru County, Kenya.
-
-
Blueprint for Access to Innovative Healthcare is Takeda’s flagship Access to Medicines initiative to accelerate global progress in the prevention and treatment of Non-Communicable Diseases (NCDs).
-
Diversity, Equity and Inclusion is an integral part of our corporate philosophy. We create an equitable environment where diversity is welcomed and everyone can bring their true self to the workplace.
-
Goal Setting and Measurement report finds decarbonization strategies are increasingly complex and current solutions may not be enough to achieve aggressive targets SOURCE: Black Veatch DESCRIPTION:May 11, 2021 /3BL Media/ - Companies of all sizes across business sectors are elevating sustainability as a core tenet of their practices, yet a new Black Veatch report discovers that many companies continue to establish targets without a clear understanding of how to achieve them. Black Veatch’s Corpor
-
Our manufacturing site in Lessines, Belgium, is pioneering wastewater circularity in the pharma industry. The facility installed a water treatment system which will be used to supplement fresh water for the drug production process...
-
We’re looking beyond the science with two of Takeda’s leaders to explore how Takeda adapted to this new normal while continuing to deliver for patients.
-
“I am in Taouyah, in Gnariwada,” said Aïssatou Nènè Baldé, a CMC midwife, shortly after the election. “This is one of the areas of increased political tension. But I go out to work because women need me.”
-
The Takeda Executive Team has joined with our employees around the globe to pledge to make the world more gender equal.
-
-
Takeda has been named a Global Top Employer for 4th consecutive year!
-
Takeda Pharmaceutical Company Limited announced that it achieved carbon neutrality in its value chain for its fiscal year 2019.
-
Leaders and clinical improvers gather virtually to share new ideas and evidence-based approaches to improve population health and health equity
-
− Takeda employees worldwide voted to add Access to Health Fund and Bridges to Development as 2020 partners
− With these new partners, Takeda's Global CSR Program contributions total JPY 12.3 billion (USD 112 million*) across 16 programs in more than 60 countries since its 2016 launch
− Takeda’s founding mission to serve patients, wherever they are, drives its commitments to prevent disease and increase access to healthcare in partnership with the global community
-
-
Ranked 3rd among pharmaceutical companies for sustainable leadership
-
Recognized for environmental sustainability, equitable pricing strategies in low- and middle-income countries, and senior executive female representation
-
-
14 Global Brands and 12 Potential New Molecular Entities will Drive Sustainable Growth
-
Takeda Confirms Commitment to Rapid Deleveraging Towards Target of 2x Net Debt / adjusted EBITDA within Fiscal Years Ending March 2022 – March 2024
-
Significant Commitment to and Investment in Carbon Neutrality that Builds on Successful Environmental Sustainability Efforts
-
-
On the FTSE4Good Developed Index, Takeda received high marks in the areas of “Climate Change,” “Customer Responsibility,” and “Corporate Governance.\" Takeda’s proactive approach to tackling environmental issues on a global scale includes...
-
- Selected by the FTSE4Good Developed Index for the 15th consecutive year
- Named to the MSCI ESG Leaders Index for the 10th consecutive year
- Rigorously evaluated by indices measuring strong performance on ESG criteria
-
SOURCE: Takeda SUMMARY:Selected by the FTSE4Good Developed Index for the 15th consecutive year Named to the MSCI ESG Leaders Index for the 10th consecutive year Rigorously evaluated by indices measuring strong performance on ESG criteria DESCRIPTION: OSAKA, July 10, 2019 /3BL Media/ --- Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has been selected for the 15th consecutive year by the FTSE4Good Developed Index, one of the world’s premier indices for
-
-
Takeda’s founding mission to serve patients, wherever they are, drives its increased commitments to disease prevention, capacity building, and access to healthcare in developing and emerging countries, in partnership with the global community.
-
Through its annual Global CSR Program, approximately 20,000 employees worldwide cast their votes, selecting City Cancer Challenge, Drugs for Neglected Diseases initiative (DNDi), SeriousFun Children’s Network, UNICEF, and the UN Foundation as 2019 partners.
-
With these programs, Takeda's contributions through its unique Global CSR Program total 10.5 billion yen for a total of 14 programs since its 2016 launch.
-
Takeda Pharmaceutical Company Limited (“Takeda”) announced the addition of five partners to its Global CSR Program for 2019, which contributes to the long-term health of people through disease prevention and capacity building in developing and...
-
Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today became the first private sector company to announce a financial commitment to the Global Fund’s Sixth Replenishment. The new pledge, consisting of JP ¥ 1 billion over five years, builds on Takeda's previous contribution to the Global Fund. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190602005021/en/ Takeda, a leading global pharmaceutical company headquarter